Sylvain Jereme M 4
4 · DEXCOM INC · Filed Mar 11, 2025
Insider Transaction Report
Form 4
DEXCOM INCDXCM
Sylvain Jereme M
EVP, Chief Financal Officer
Transactions
- Award
Common Stock
2025-03-08+35,906→ 119,684 total - Sale
Common Stock
2025-03-10$73.22/sh−2,670$195,489→ 139,812 total - Sale
Common Stock
2025-03-10$74.04/sh−3,203$237,151→ 136,609 total - Sale
Common Stock
2025-03-10$74.70/sh−1,127$84,189→ 135,482 total - Award
Common Stock
2025-03-08+22,798→ 142,482 total
Footnotes (6)
- [F1]Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
- [F2]Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
- [F3]This transaction was executed in multiple trades at prices ranging from $72.56 to $73.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $73.56 to $74.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $74.61 to $74.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F6]Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 252 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025.